BMS-986393 + alnuctamab

BMS-986393 + alnuctamab is a combination of two investigational immunotherapies for relapsed or refractory multiple myeloma. **BMS-986393 (arlocabtagene autoleucel)** is an autologous chimeric antigen receptor (CAR) T cell therapy that targets G protein-coupled receptor, family C, group 5, member D (**GPRC5D**) on multiple myeloma cells. **Alnuctamab** is a bispecific T cell engager antibody that binds both B-cell maturation antigen (**BCMA**) on myeloma cells and CD3 on T cells, facilitating T-cell mediated lysis of malignant plasma cells. The combination aims to harness dual antigen targeting and T-cell engagement to achieve deeper and more durable responses in heavily pretreated patients. Both agents are being developed by Bristol Myers Squibb and are currently in early-phase clinical trials in combination for relapsed/refractory multiple myeloma[3][5][9].

Other names

arlocabtagene autoleucel + alnuctamab